Exhibit B

```
1
 2
 3
     IN RE:
                               :SUPERIOR COURT OF
     PELVIC MESH/GYNECARE
                               :NEW JERSEY
 4
     LITIGATION
                               :LAW DIVISION -
                               :ATLANTIC COUNTY
 5
                               :MASTER CASE 6341-10
 6
                               :CASE NO. 291 CT
 7
     CONFIDENTIAL-SUBJECT TO STIPULATION AND ORDER OF
 8
                     CONFIDENTIALITY
 9
                  September 12, 2012
10
11
12
               Volume I of the transcript of the
13
     Deposition of CHARLOTTE OWENS, M.D., called for
14
     Videotaped Examination in the above-captioned
15
     matter, said deposition taken pursuant to
16
     Superior Court Rules of Practice and Procedure,
17
    by and before JoRita B. Meyer, a Certified
18
     Realtime Reporter, Registered Merit Reporter,
19
     and Certified Court Reporter for the State of
20
     Georgia, at the offices of Troutman Sanders,
21
     600 Peachtree Street Northeast, Atlanta,
     Georgia, commencing at 9:39 a.m.
22
23
24
              GOLKOW TECHNOLOGIES, INC.
          877.370.3377 ph 917.951.5672 fax
25
                   deps@qolkow.com
```

```
decide if they want to learn more about
1
2
           the system, and ultimately will use
           their training, education, and
3
           experience, plus this document, to
4
           decide if they want to use it.
5
6
      BY MR. SLATER:
7
           Q.
                Did you understand that it was
      necessary to clearly and unambiguously
8
      communicate all necessary contraindications,
 9
10
      warnings and precautions, and adverse reactions
      to physicians through the IFU?
11
                I understand the document should be
12
      clear and unambiguous, yes.
13
14
           Q.
                Did you understand that it was
      necessary for Gynecare, to the extent that a
15
      risk was understood to exist with the PROLIFT,
16
17
      to communicate it in the IFU as opposed to
      assuming that surgeons would figure out that
18
19
      risk on their own?
20
                I don't think you're giving surgeons
           Α.
      enough credit. Surgeons don't have to figure
21
22
      out the complications of an area that they
23
      operate. Surgeons are trained to know the
      complications of the area in which they
24
25
      operate.
```

```
BY MR. SLATER:
1
                Does it mean too much tension?
2
           Ο.
3
           Α.
                It's not that simple.
                How would a surgeon doing the
4
           Q.
5
      procedure be able to objectively verify, based
6
      on an objective standard, that they had placed
 7
      or not placed the mesh with excessive tension?
8
                They would be able to look at the
9
      repair after surgery and see if it looks
10
      relaxed or see if it looks like it's under
      tension.
11
12
           0.
                So that's how they would do it?
13
           Α.
                That's generally how it was done.
14
           Q.
                Did you ever perform the PROLIFT
15
      procedure?
16
                On the cadavers, yes. In live
      people, because I was not practicing during my
17
18
      tenure at Ethicon, no.
19
           Q.
                Did you ever on your own, without any
      other surgeon performing the procedure -- did
20
      you ever place Gynemesh in a human's body?
21
22
           Α.
                No.
23
           Q.
                Look at the adverse reactions,
24
      please.
               It was your understanding that you
25
      needed to list each of the adverse reactions
```

```
1
      that were known to you in Medical Affairs in
      this section, correct?
2
3
           Α.
                Yes.
4
           0.
                And you understood that if you failed
      to list adverse reactions that you were aware
5
 6
      of, that that would render that warning
 7
      deficient to some extent, correct?
           Α.
                Deficient?
 8
 9
                MR. BROWN: Objection.
10
                THE WITNESS:
                              I would say that we
11
           listed the adverse reactions that we
12
           knew were adequate and sufficient for
13
           this document.
      BY MR. SLATER:
14
15
                Well, you just said a moment ago you
16
      agreed with me that you understood you were
17
      supposed to list each of the adverse reactions
18
      that you in Medical Affairs knew existed at the
      time of launch, correct?
19
20
                We listed the adverse events that we
           Α.
21
      knew to be directly related to the information
      that we had at this time.
22
23
                Okay. Were there risks -- well,
           Q.
24
      rephrase.
25
                You see where it says, at the end of
```